Ligand Pharmaceuticals (LGND +3.44%) reported that its CLO & Secretary, Andrew Reardon, exercised 5,000 stock options and immediately sold the resulting common shares for a transaction value of approximately $1.03 million, as disclosed in a SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold (direct) | 5,000 |
| Transaction value | $1.0 million |
| Post-transaction shares (direct) | 36,869 |
| Post-transaction value (direct ownership) | ~$7.70 million |
Transaction value based on SEC Form 4 weighted average purchase price ($206.35); post-transaction value based on March 4, 2026 market close ($206.35).
Key questions
- How does the size of this transaction compare to Reardon's recent historical sell activity?
This 5,000-share sale is materially larger than Reardon's median sell transaction of 750 shares during the recent period (February 2025 to March 2026), and exceeds the typical 1.73% of holdings per sale observed in that timeframe. - Did the transaction have a lasting impact on Reardon's equity exposure to Ligand Pharmaceuticals?
While direct common stock holdings declined by 11.94%, Reardon continues to maintain substantial option-based exposure, with 54,444 employee stock options (direct), preserving the ability to rebuild or increase equity participation through future exercises. - Was this transaction driven by a conversion-for-sale mechanism, and what are the implications?
Yes, the 5,000 shares sold were created via immediate option exercise and sale, indicating the transaction was structured for liquidity rather than a reduction of long-held shares; this approach leaves the underlying option pool intact for future use. - How does the current market context inform the transaction's timing and valuation?
The sale occurred when Ligand Pharmaceuticals shares were priced at around $206.35 per share, during a period of strong price performance (81.3% one-year total return as of March 4, 2026), allowing Reardon to monetize derivative awards amid elevated market capitalization.
Company overview
| Metric | Value |
|---|---|
| Price (as of market close March 4, 2026) | $211.48 |
| Market capitalization | $3.8 billion |
| Revenue (TTM) | $268.09 million |
| 1-year price change | 81.6% |
* 1-year performance calculated using March 27, 2026 as the reference date.
Company snapshot
- Ligand Pharmaceuticals' portfolio includes commercialized therapies such as Kyprolis, Evomela, Veklury, Rylaze, and Captisol-enabled products, targeting oncology, infectious diseases, autoimmune disorders, and rare conditions.
- The company generates revenue primarily through licensing agreements, royalties, and material sales, leveraging a partnership-driven model with pharmaceutical companies to commercialize and develop new medicines.
- Ligand Pharmaceuticals' primary customers are global pharmaceutical and biotechnology firms seeking advanced drug discovery technologies, clinical-stage assets, and proprietary enabling platforms.
Ligand Pharmaceuticals operates as a biopharmaceutical innovator with a scalable, asset-light business model focused on technology licensing and royalty streams. Its diversified portfolio and partnership approach enable broad exposure to leading therapeutic markets while maintaining a lean operational footprint. The company’s strategic emphasis on platform technologies and commercial collaborations provides a competitive advantage through recurring revenue and access to multiple growth opportunities.
What this transaction means for investors
Andrew Reardon is Ligand Pharmaceuticals' Chief Legal Officer and Corporate Secretary — the executive overseeing legal affairs, compliance, and governance. On March 4, he exercised 5,000 stock options at $52.27 and immediately sold the resulting shares at market prices averaging around $206, generating roughly $1.03 million in proceeds. That gap between exercise price and sale price — about $154 per share — is the point. This is how equity compensation is designed to work: options granted years ago become valuable when the stock appreciates, and the holder monetizes them. It's not a sale of long-held shares signaling a change in conviction.
The timing is worth noting for readers. Ligand has had a strong run, and the stock's roughly 81% one-year return heading into the transaction gave Reardon a favorable window to act. The transaction was also pre-planned — filed under a 10b5-1 arrangement adopted in November 2025, meaning it was scheduled well before execution. Ligand delivered 48% royalty revenue growth in 2025 and is guiding for $200–$225 million in royalty revenue in 2026. Reardon still holds 54,444 options, so his long-term exposure to that growth story remains intact.
